Stock Runners: Repligen (NASDAQ:RGEN), Durata Therapeutics (NASDAQ:DRTX), Acadia Realty Trust (NYSE:AKR), International Game Technology (NYSE:IGT), DDR Corp. (NYSE:DDR)

Repligen Corp. (NASDAQ:RGEN) released its earnings data on Monday, 11 Aug 2014. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s … Continue reading Stock Runners: Repligen (NASDAQ:RGEN), Durata Therapeutics (NASDAQ:DRTX), Acadia Realty Trust (NYSE:AKR), International Game Technology (NYSE:IGT), DDR Corp. (NYSE:DDR)

Chris Lewis09/0409/04

Trader’s Recap – Johnson & Johnson (NYSE:JNJ) , Twitter (NYSE:TWTR) , PRAA, Repligen (NASDAQ:RGEN) , Lincoln Educational Services (NASDAQ:LINC)

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company’s common stock. Repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Johnson & … Continue reading Trader’s Recap – Johnson & Johnson (NYSE:JNJ) , Twitter (NYSE:TWTR) , PRAA, Repligen (NASDAQ:RGEN) , Lincoln Educational Services (NASDAQ:LINC)

Chris Lewis07/2207/22

Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation (NASDAQ:CELG) stock performance was 0.88% in last session and finished … Continue reading Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Richard Atkins06/2606/26

Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -6.32% in last session and finished the day at $6.38. Traded volume was 21.04million shares in the last … Continue reading Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Mark DeFrance06/1306/13

NASDAQ Recent Insider Buying: Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Equinix Inc (NASDAQ:EQIX), AspenBio Pharma (NASDAQ:APPY)

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Kovner Bruce purchased 1,250,000 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 1.01% in last session and finished the day at $4.01. Traded volume was 1.90million shares in the last … Continue reading NASDAQ Recent Insider Buying: Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Equinix Inc (NASDAQ:EQIX), AspenBio Pharma (NASDAQ:APPY)

Colin Pettis04/2204/22

Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day at $2.60. Traded volume was 16.17million shares in the last … Continue reading Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

John Bellich04/1604/16